Manifestation of eosinophilic granulomatosis with polyangiitis in head and neck

被引:0
|
作者
Petersen, Hannes [1 ]
Goetz, Paul [1 ]
Both, Marcus [2 ]
Hey, Matthias [1 ]
Ambrosch, Petra [1 ]
Bremer, Jan Phillip [3 ,4 ]
Holle, Julia [3 ,4 ]
Moosig, Frank [3 ,4 ]
Laudien, Martin [1 ]
机构
[1] Univ Kiel, Dept Otorhinolaryngol Head & Neck Surg, D-24103 Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Dept Radiol & Neuroradiol, Kiel, Germany
[3] Klinikum Bad Bramstedt, Dept Rheumatol, Bad Bramstedt, Germany
[4] Univ Hosp Schleswig Holstein, Bad Bramstedt, Germany
关键词
EGPA; ENT; eosinophilic granulomatosis with polyangiitis; Churg-Strauss syndrome; head and neck; CHURG-STRAUSS-SYNDROME; TERM-FOLLOW-UP; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; ALLERGIC GRANULOMATOSIS; OLFACTORY DYSFUNCTION; AIR-FLOW; PREVALENCE; VASCULITIS; POPULATION; IMPAIRMENT;
D O I
10.4193/Rhin14.074
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Introduction: Besides an obvious clinical involvement of the ear, nose and throat (ENT)-region in Eosinophilic Granulomatosis with Polyangiitis (EGPA), systematic data is sparse. Only a few case series and case reports are available that particularly describe rhinological, otological or other manifestations of EGPA in the ENT-region. Therefore, the objective of this study is to systematically describe data on ENT-region involvement in a large series of EGPA patients. Method: EGPA patients examined in the Department of Otorhinolaryngology of the Christian-Albrechts-University of Kiel between 1990 and 2010 were included in the study. Criteria for ENT-manifestation were assigned to five subgroups (history, ENT examination, audiological and rhinological diagnostic findings and cranial MRI) and documented cumulatively. EGPA patients were examined in a standardized way based on the validated Ear Nose and Throat Activity Score (ENTAS) or its precursor, including audiological and rhinological diagnostic findings. MRI scans were analysed to further evaluate ENT involvement. Results: A total of 95 EGPA patients were included in the study. In approximately 80% of them, ENT-involvement was documented and the assumption of a frequent rhinological manifestation in patients with EGPA was confirmed. Moreover, the data reveals remarkable evidence for an otological manifestation. A missing correlation between the rhinological and the otological manifestation indicates an independent autoimmune-inflammatory process for this manifestation. Conclusion: The data of the largest monocentric study presented here confirms the hypothesis of a frequent ENT involvement in EGPA patients, in whom rhinological and otological manifestations are most common Therefore, treatment should include long term follow-up and should be managed interdisciplinary.
引用
收藏
页码:277 / 285
页数:9
相关论文
共 50 条
  • [31] Rituximab for eosinophilic granulomatosis with polyangiitis
    Brooks, Helen
    Clark, Anna
    Van Epps, Heather
    LANCET RHEUMATOLOGY, 2022, 4 (01): : E19 - E19
  • [33] Benralizumab in Eosinophilic Granulomatosis with Polyangiitis
    Cottu, Adrien
    Groh, Matthieu
    Desaintjean, Charlene
    Marchand-Adam, Sylvain
    Guillevin, Loic
    Puechal, Xavier
    Lazaro, Estibaliz
    Samson, Maxime
    Taille, Camille
    Durel, Cecile-Audrey
    Diot, Elisabeth
    Nicolas, Sarah
    Guilleminault, Laurent
    Ebbo, Mikael
    Cathebras, Pascal
    Dupin, Clairelyne
    Yildiz, Halil
    Belfeki, Nabil
    Pugnet, Gregory
    Chauvin, Pierre
    Jouneau, Stephane
    Lifermann, Francois
    Martellosio, Jean-Philippe
    Cottin, Vincent
    Terrier, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1351 - 1354
  • [34] Prevasculitic Eosinophilic Granulomatosis With Polyangiitis
    Burtson, Kathryn M.
    Bishop, Jonathan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [35] EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS : NOT FOR THE LIGHTHEARTED
    Gopalarathinam, Rajesh
    Indramohan, Pavithra
    Vishwanathan, Swathi
    Madhanakumar, Aarthi
    Sharma, Tarun
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 : S617 - S618
  • [36] Benralizumab in eosinophilic granulomatosis with polyangiitis
    Laorden, Daniel
    Romero, David
    Dominguez-Ortega, Javier
    MEDICINA CLINICA, 2022, 158 (10): : 441 - +
  • [37] Biologics for eosinophilic granulomatosis with polyangiitis
    Caminati, Marco
    Maule, Matteo
    Bello, Federica
    Emmi, Giacomo
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 23 (01) : 36 - 43
  • [38] Mepolizumab for eosinophilic granulomatosis with polyangiitis
    Loïc Guillevin
    Nature Reviews Rheumatology, 2017, 13 : 518 - 519
  • [39] Benralizumab in eosinophilic granulomatosis with polyangiitis
    Laorden, Daniel
    Romero, David
    Dominguez-Ortega, Javier
    MEDICINA CLINICA, 2022, 158 (09): : 441 - 442
  • [40] Acute heart failure with dilated cardiomyopathy as the first manifestation of eosinophilic granulomatosis with polyangiitis
    Chen, Y. T.
    Liu, W. S.
    Su, K. Y.
    Hsu, Y. H.
    Chang, C. H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (02) : E125 - E128